Noma

Infectious Disease MONDO:0017124 Pathograph 2 Bacterial Infection Neglected tropical disease

Noma (cancrum oris) is a devastating gangrenous disease that leads to severe tissue destruction in the face and is associated with high morbidity and mortality. It affects predominantly malnourished children in sub-Saharan Africa and is preceded by acute necrotizing gingivitis. Without treatment, mortality is 70-90%. Survivors suffer orofacial disfigurement, trismus, and functional impairment.

Ask OpenScientist

Ask a research question about Noma. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

2
Pathophys.
10
Phenotypes
2
Pathograph
3
Treatments
12
References
1
Deep Research
⚙

Pathophysiology

2
Polymicrobial infection with tissue necrosis
Polymicrobial infection drives rapid orofacial tissue necrosis. The etiology is multifactorial with malnutrition as an ever-present factor, often in combination with concomitant diseases such as measles, malaria, and HIV. Acute necrotizing gingivitis is the antecedent lesion, and progression to noma requires infection by a consortium of microorganisms with Fusobacterium necrophorum and Prevotella intermedia as suspected key players.
epithelial cell link macrophage link neutrophil link
response to bacterium link ⚠ ABNORMAL inflammatory response link ⚠ ABNORMAL cell death link ⚠ ABNORMAL
Show evidence (3 references)
PMID:26437752 SUPPORT
"The characteristic tissue necrosis is produced by a polymicrobial infection."
The abstract attributes tissue necrosis to polymicrobial infection.
PMID:10522212 SUPPORT
"Acute necrotizing gingivitis (ANG) is considered the antecedent lesion. Current studies suggest that evolution of ANG to noma requires infection by a consortium of microorganisms with Fusobacterium necrophorum and Prevotella intermedia as the suspected key players."
Describes the pathogenetic sequence from ANG to noma and identifies the key microbial players.
PMID:12002813 SUPPORT
"Infections and malnutrition impair the immune system, and this is the common denominator for the occurrence of noma."
Confirms that immunosuppression from infections and malnutrition is the central pathogenetic mechanism.
Immunodeficiency from malnutrition and infection
Malnutrition acts synergistically with endemic infections to promote an immunodeficient state. Noma results from the interaction of general and local factors with a weakened immune system as the common denominator.
macrophage link neutrophil link
immune response link ⚠ ABNORMAL response to bacterium link ⚠ ABNORMAL
Downstream
Polymicrobial infection with tissue necrosis Impaired host defenses from malnutrition and infection permit antecedent oral lesions to progress to the polymicrobial gangrenous tissue necrosis that defines noma.
Show evidence (2 references)
PMID:10522212 SUPPORT
"Malnutrition acts synergistically with endemic infections in promoting an immunodeficient state, and noma results from the interaction of general and local factors with a weakened immune system as the common denominator."
Directly describes the synergistic immunosuppressive mechanism of malnutrition and infection in noma pathogenesis.
PMID:28093536 SUPPORT
"The etiology of noma is multifactorial with malnutrition as an ever present factor, often in combination with concomitant diseases, such as measles, malaria, and human immunodeficiency virus (HIV), and poor oral hygiene."
Confirms the multifactorial etiology with malnutrition as a constant factor alongside infectious comorbidities.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Noma Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

10
Digestive 2
Dysphagia Dysphagia (HP:0002015)
Show evidence (1 reference)
PMID:41282445 SUPPORT Human Clinical
"Common clinical issues included eating difficulties (77%), speech challenges (54.4%), and trismus (38.8%)."
Clinical data from 103 noma survivors shows eating difficulties in 77% of patients.
Malnutrition Malnutrition (HP:0004395)
Show evidence (2 references)
PMID:28093536 SUPPORT
"The etiology of noma is multifactorial with malnutrition as an ever present factor, often in combination with concomitant diseases, such as measles, malaria, and human immunodeficiency virus (HIV), and poor oral hygiene."
Malnutrition is identified as an ever-present factor in noma etiology.
PMID:12837347 SUPPORT
"malnutrition, a compromised immune system, poor oral hygiene and a lesion of the gingival mucosal barrier, and an unidentified bacterial factor acting as a trigger for the disease."
Lists malnutrition as a key element of the plausible aetiology of noma.
Head and Neck 4
Oral ulcer Oral ulcer (HP:0000155)
Show evidence (2 references)
PMID:12002813 SUPPORT
"Acute necrotizing gingivitis (ANG) and oral herpetic ulcers are considered the antecedent lesions, and ongoing studies suggest that the rapid progression of these precursor lesions to noma requires infection by a consortium of micro-organisms"
Identifies necrotizing gingivitis and oral herpetic ulcers as the precursor lesions of noma.
PMID:35576473 SUPPORT
"According to the WHO, noma comprises five sequential 'stages': (1) necrotizing gingivitis, (2) edema, (3) gangrene, (4) scarring and (5) sequelae."
WHO staging confirms necrotizing gingivitis as the initial stage of noma disease progression.
Facial edema Facial edema (HP:0000282)
Show evidence (1 reference)
PMID:35576473 SUPPORT
"According to the WHO, noma comprises five sequential 'stages': (1) necrotizing gingivitis, (2) edema, (3) gangrene, (4) scarring and (5) sequelae."
The WHO staging system identifies edema as the second stage of noma progression.
Trismus Trismus (HP:0000211)
Show evidence (2 references)
PMID:41282445 SUPPORT Human Clinical
"Common clinical issues included eating difficulties (77%), speech challenges (54.4%), and trismus (38.8%)."
Clinical data from 103 noma survivors shows trismus in 38.8% of patients.
PMID:12655218 SUPPORT
"Patients who survive noma generally suffer from its sequelae, including serious facial disfigurement, trismus, oral incontinence, and speech problems."
Historical review identifies trismus as a recognized sequela of noma survival.
Dental abnormalities Abnormality of the dentition (HP:0000164)
Show evidence (1 reference)
PMID:12002813 SUPPORT
"Cancrum oris (Noma) is a devastating infectious disease which destroys the soft and hard tissues of the oral and para-oral structures."
Confirms destruction of hard tissues (including teeth and bone) as a feature of noma.
Metabolism 1
Fever Fever (HP:0001945)
Show evidence (1 reference)
PMID:26740267 SUPPORT Human Clinical
"presented with recurrent fever, progressive pallor, lymphadenopathy and a raw area on the right cheek, with discharging sinus. The necrotising infection of the face developed after one and half months of febrile illness."
Case report documents recurrent fever in a child who developed necrotising facial infection diagnosed as noma.
Nervous System 1
Speech impairment Abnormal speech pattern (HP:0002167)
Show evidence (2 references)
PMID:41282445 SUPPORT Human Clinical
"Common clinical issues included eating difficulties (77%), speech challenges (54.4%), and trismus (38.8%)."
Clinical data from 103 noma survivors shows speech challenges in 54.4% of patients.
PMID:12655218 SUPPORT
"Patients who survive noma generally suffer from its sequelae, including serious facial disfigurement, trismus, oral incontinence, and speech problems."
Confirms speech problems as a recognized sequela of noma.
Constitutional 1
Orofacial gangrene Gangrene (HP:0100758)
Show evidence (3 references)
PMID:26437752 SUPPORT
"Noma is an aggressive orofacial gangrenous pathology that damages hard and soft tissues of the mouth and the face."
The abstract describes noma as an orofacial gangrenous pathology.
PMID:12837347 SUPPORT
"Noma (cancrum oris) is a devastating gangrenous disease that leads to severe tissue destruction in the face and is associated with high morbidity and mortality."
Confirms noma as a gangrenous disease with severe facial tissue destruction.
PMID:28093536 SUPPORT
"The pathogenesis is a fast-spreading, noncontagious gangrenous infection occurring in the face, often preceded by acute necrotizing gingivitis, and stomatitis."
Characterizes the pathogenesis as a fast-spreading gangrenous infection of the face.
Other 1
Facial disfigurement Abnormality of the face (HP:0000271)
Show evidence (3 references)
PMID:12655218 SUPPORT
"Patients who survive noma generally suffer from its sequelae, including serious facial disfigurement, trismus, oral incontinence, and speech problems."
Describes the key sequelae of noma survivors including facial disfigurement.
PMID:35576473 SUPPORT
"Most survivors of noma live with gross physical disfigurement and disability, and with impaired psychosocial functioning"
Confirms that most noma survivors experience gross physical disfigurement.
PMID:41282445 SUPPORT Human Clinical
"Noma is a severe, rapidly progressing necrotizing infection that predominantly affects children in resource-limited settings and can lead to devastating facial disfigurement."
Clinical study of 103 noma survivors confirms devastating facial disfigurement as a sequela.
💊

Treatments

3
Antibiotic Therapy
Action: Pharmacotherapy NCIT:C15986
Early antibiotic treatment is used during active noma to prevent gangrene or reduce the extent of tissue destruction.
Show evidence (1 reference)
PMID:28093536 SUPPORT
"Early treatment with antibiotics may prevent gangrene or reduce its extent."
Review article supports antibiotics as early treatment to prevent or limit gangrene.
Surgical Rehabilitation
Action: surgical procedure MAXO:0000004
Survivors with late-stage sequelae often require complex reconstructive surgery and rehabilitation to address facial disfigurement and functional impairment.
Show evidence (2 references)
PMID:28093536 SUPPORT
"Late treatment consists of surgical rehabilitation, which is often complex."
Review article supports surgical rehabilitation as late treatment for noma sequelae.
PMID:41282445 SUPPORT Human Clinical
"Although surgical reconstruction is effective, high complication rates and the need for multiple surgical procedures underscore the importance of comprehensive long-term care, including rehabilitation and psychological support."
Clinical survivor cohort describes reconstruction, repeated procedures, and rehabilitation needs after noma.
Nutritional Support
Action: dietary intervention MAXO:0000088
Nutritional support and correction of malnutrition are important supportive interventions because malnutrition is an ever-present factor in noma etiology and contributes to immune compromise.
Show evidence (1 reference)
DOI:10.58541/001c.71441 SUPPORT Human Clinical
"Immediate treatment began following admission, including intravenous antibiotics, oral care and nutritional supplementation, before a definitive clinical diagnosis of noma was made after a biopsy, which ruled out malignancy."
Clinical report describes nutritional supplementation as part of immediate treatment for a patient diagnosed with noma.
{ }

Source YAML

click to show 
name: Noma
creation_date: '2026-01-26T15:56:41Z'
updated_date: '2026-05-02T00:00:00Z'
category: Infectious Disease
description: >-
  Noma (cancrum oris) is a devastating gangrenous disease that leads to severe
  tissue destruction in the face and is associated with high morbidity and
  mortality. It affects predominantly malnourished children in sub-Saharan Africa
  and is preceded by acute necrotizing gingivitis. Without treatment, mortality
  is 70-90%. Survivors suffer orofacial disfigurement, trismus, and functional
  impairment.
disease_term:
  term:
    id: MONDO:0017124
    label: noma
  preferred_term: Noma
parents:
- Bacterial Infection
- Neglected tropical disease
pathophysiology:
- name: Polymicrobial infection with tissue necrosis
  description: >-
    Polymicrobial infection drives rapid orofacial tissue necrosis. The etiology
    is multifactorial with malnutrition as an ever-present factor, often in
    combination with concomitant diseases such as measles, malaria, and HIV. Acute
    necrotizing gingivitis is the antecedent lesion, and progression to noma
    requires infection by a consortium of microorganisms with Fusobacterium
    necrophorum and Prevotella intermedia as suspected key players.
  cell_types:
  - preferred_term: epithelial cell
    term:
      id: CL:0000066
      label: epithelial cell
  - preferred_term: macrophage
    term:
      id: CL:0000235
      label: macrophage
  - preferred_term: neutrophil
    term:
      id: CL:0000775
      label: neutrophil
  biological_processes:
  - preferred_term: response to bacterium
    modifier: ABNORMAL
    term:
      id: GO:0009617
      label: response to bacterium
  - preferred_term: inflammatory response
    modifier: ABNORMAL
    term:
      id: GO:0006954
      label: inflammatory response
  - preferred_term: cell death
    modifier: ABNORMAL
    term:
      id: GO:0008219
      label: cell death
  evidence:
  - reference: PMID:26437752
    reference_title: "[Noma/Cancrum oris: a neglected disease]."
    supports: SUPPORT
    snippet: "The characteristic tissue necrosis is produced by a polymicrobial infection."
    explanation: The abstract attributes tissue necrosis to polymicrobial infection.
  - reference: PMID:10522212
    reference_title: "Noma (cancrum oris): questions and answers."
    supports: SUPPORT
    snippet: >-
      Acute necrotizing gingivitis (ANG) is considered the antecedent lesion.
      Current studies suggest that evolution of ANG to noma requires infection by
      a consortium of microorganisms with Fusobacterium necrophorum and Prevotella
      intermedia as the suspected key players.
    explanation: >-
      Describes the pathogenetic sequence from ANG to noma and identifies the key
      microbial players.
  - reference: PMID:12002813
    reference_title: "Oro-facial gangrene (noma/cancrum oris): pathogenetic mechanisms."
    supports: SUPPORT
    snippet: >-
      Infections and malnutrition impair the immune system, and this is the
      common denominator for the occurrence of noma.
    explanation: >-
      Confirms that immunosuppression from infections and malnutrition is the
      central pathogenetic mechanism.
- name: Immunodeficiency from malnutrition and infection
  description: >-
    Malnutrition acts synergistically with endemic infections to promote an
    immunodeficient state. Noma results from the interaction of general and local
    factors with a weakened immune system as the common denominator.
  cell_types:
  - preferred_term: macrophage
    term:
      id: CL:0000235
      label: macrophage
  - preferred_term: neutrophil
    term:
      id: CL:0000775
      label: neutrophil
  biological_processes:
  - preferred_term: immune response
    modifier: ABNORMAL
    term:
      id: GO:0006955
      label: immune response
  - preferred_term: response to bacterium
    modifier: ABNORMAL
    term:
      id: GO:0009617
      label: response to bacterium
  evidence:
  - reference: PMID:10522212
    reference_title: "Noma (cancrum oris): questions and answers."
    supports: SUPPORT
    snippet: >-
      Malnutrition acts synergistically with endemic infections in promoting an
      immunodeficient state, and noma results from the interaction of general and
      local factors with a weakened immune system as the common denominator.
    explanation: >-
      Directly describes the synergistic immunosuppressive mechanism of
      malnutrition and infection in noma pathogenesis.
  - reference: PMID:28093536
    reference_title: "Noma: Overview of a Neglected Disease and Human Rights Violation."
    supports: SUPPORT
    snippet: >-
      The etiology of noma is multifactorial with malnutrition as an ever present
      factor, often in combination with concomitant diseases, such as measles,
      malaria, and human immunodeficiency virus (HIV), and poor oral hygiene.
    explanation: >-
      Confirms the multifactorial etiology with malnutrition as a constant factor
      alongside infectious comorbidities.
  downstream:
  - target: Polymicrobial infection with tissue necrosis
    description: >-
      Impaired host defenses from malnutrition and infection permit antecedent
      oral lesions to progress to the polymicrobial gangrenous tissue necrosis
      that defines noma.
    evidence:
    - reference: PMID:10522212
      reference_title: "Noma (cancrum oris): questions and answers."
      supports: SUPPORT
      snippet: >-
        Malnutrition acts synergistically with endemic infections in promoting an
        immunodeficient state, and noma results from the interaction of general
        and local factors with a weakened immune system as the common
        denominator. Acute necrotizing gingivitis (ANG) is considered the
        antecedent lesion. Current studies suggest that evolution of ANG to noma
        requires infection by a consortium of microorganisms
      explanation: >-
        Links malnutrition- and infection-associated immunodeficiency to the
        transition from antecedent oral lesions into polymicrobial noma.
phenotypes:
- name: Orofacial gangrene
  category: Craniofacial
  description: >-
    Noma is defined by rapidly spreading gangrenous necrosis of the orofacial
    tissues, destroying both soft and hard tissues of the mouth and face.
  phenotype_term:
    preferred_term: Orofacial gangrene
    term:
      id: HP:0100758
      label: Gangrene
  evidence:
  - reference: PMID:26437752
    reference_title: "[Noma/Cancrum oris: a neglected disease]."
    supports: SUPPORT
    snippet: >-
      Noma is an aggressive orofacial gangrenous pathology that damages hard and
      soft tissues of the mouth and the face.
    explanation: The abstract describes noma as an orofacial gangrenous pathology.
  - reference: PMID:12837347
    reference_title: "Noma: an \"infectious\" disease of unknown aetiology."
    supports: SUPPORT
    snippet: >-
      Noma (cancrum oris) is a devastating gangrenous disease that leads to severe
      tissue destruction in the face and is associated with high morbidity and
      mortality.
    explanation: >-
      Confirms noma as a gangrenous disease with severe facial tissue destruction.
  - reference: PMID:28093536
    reference_title: "Noma: Overview of a Neglected Disease and Human Rights Violation."
    supports: SUPPORT
    snippet: >-
      The pathogenesis is a fast-spreading, noncontagious gangrenous infection
      occurring in the face, often preceded by acute necrotizing gingivitis, and
      stomatitis.
    explanation: >-
      Characterizes the pathogenesis as a fast-spreading gangrenous infection of
      the face.
- name: Oral ulcer
  category: Craniofacial
  description: >-
    Acute necrotizing gingivitis (ANG), characterized by ulceration of the oral
    mucosa, is considered the antecedent lesion of noma. The oral ulcerative stage
    precedes progression to gangrene.
  phenotype_term:
    preferred_term: Necrotizing oral ulceration
    term:
      id: HP:0000155
      label: Oral ulcer
  evidence:
  - reference: PMID:12002813
    reference_title: "Oro-facial gangrene (noma/cancrum oris): pathogenetic mechanisms."
    supports: SUPPORT
    snippet: >-
      Acute necrotizing gingivitis (ANG) and oral herpetic ulcers are considered
      the antecedent lesions, and ongoing studies suggest that the rapid
      progression of these precursor lesions to noma requires infection by a
      consortium of micro-organisms
    explanation: >-
      Identifies necrotizing gingivitis and oral herpetic ulcers as the precursor
      lesions of noma.
  - reference: PMID:35576473
    reference_title: "Is noma a neglected/overlooked tropical disease?"
    supports: SUPPORT
    snippet: >-
      According to the WHO, noma comprises five sequential 'stages': (1)
      necrotizing gingivitis, (2) edema, (3) gangrene, (4) scarring and (5)
      sequelae.
    explanation: >-
      WHO staging confirms necrotizing gingivitis as the initial stage of noma
      disease progression.
- name: Facial edema
  category: Craniofacial
  description: >-
    Edema of the face is the second stage in the WHO classification of noma,
    occurring after necrotizing gingivitis and before gangrene develops.
  phenotype_term:
    preferred_term: Facial edema
    term:
      id: HP:0000282
      label: Facial edema
  evidence:
  - reference: PMID:35576473
    reference_title: "Is noma a neglected/overlooked tropical disease?"
    supports: SUPPORT
    snippet: >-
      According to the WHO, noma comprises five sequential 'stages': (1)
      necrotizing gingivitis, (2) edema, (3) gangrene, (4) scarring and (5)
      sequelae.
    explanation: >-
      The WHO staging system identifies edema as the second stage of noma
      progression.
- name: Fever
  category: Constitutional
  description: >-
    Fever can occur during active noma presentations and is described in acute
    noma clinical contexts.
  phenotype_term:
    preferred_term: Fever
    term:
      id: HP:0001945
      label: Fever
  evidence:
  - reference: PMID:26740267
    reference_title: "Noma in a child with acute leukaemia: when the 'face of poverty' finds an ally."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      presented with recurrent fever, progressive pallor, lymphadenopathy and a
      raw area on the right cheek, with discharging sinus. The necrotising
      infection of the face developed after one and half months of febrile
      illness.
    explanation: >-
      Case report documents recurrent fever in a child who developed necrotising
      facial infection diagnosed as noma.
- name: Facial disfigurement
  category: Craniofacial
  description: >-
    Survivors of noma suffer severe facial disfigurement including destruction of
    orofacial tissues and bone, with gross physical disfigurement and disability.
  phenotype_term:
    preferred_term: Orofacial disfigurement
    term:
      id: HP:0000271
      label: Abnormality of the face
  evidence:
  - reference: PMID:12655218
    reference_title: "A history of noma, the \"Face of Poverty\"."
    supports: SUPPORT
    snippet: >-
      Patients who survive noma generally suffer from its sequelae, including
      serious facial disfigurement, trismus, oral incontinence, and speech
      problems.
    explanation: >-
      Describes the key sequelae of noma survivors including facial disfigurement.
  - reference: PMID:35576473
    reference_title: "Is noma a neglected/overlooked tropical disease?"
    supports: SUPPORT
    snippet: >-
      Most survivors of noma live with gross physical disfigurement and
      disability, and with impaired psychosocial functioning
    explanation: >-
      Confirms that most noma survivors experience gross physical disfigurement.
  - reference: PMID:41282445
    reference_title: "Patterns of Noma (Cancrum Oris) Survivors in Ethiopia: A Retrospective, Multicentric, Cross-sectional Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Noma is a severe, rapidly progressing necrotizing infection that
      predominantly affects children in resource-limited settings and can lead to
      devastating facial disfigurement.
    explanation: >-
      Clinical study of 103 noma survivors confirms devastating facial
      disfigurement as a sequela.
- name: Dysphagia
  category: Craniofacial
  description: >-
    Eating difficulties are a major functional impairment in noma survivors,
    reported in 77% of patients in an Ethiopian cohort study. Tissue destruction
    in the oral cavity and jaw impairs mastication and swallowing.
  phenotype_term:
    preferred_term: Eating difficulties
    term:
      id: HP:0002015
      label: Dysphagia
  evidence:
  - reference: PMID:41282445
    reference_title: "Patterns of Noma (Cancrum Oris) Survivors in Ethiopia: A Retrospective, Multicentric, Cross-sectional Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Common clinical issues included eating difficulties (77%), speech challenges
      (54.4%), and trismus (38.8%).
    explanation: >-
      Clinical data from 103 noma survivors shows eating difficulties in 77% of
      patients.
- name: Speech impairment
  category: Craniofacial
  description: >-
    Speech challenges are a common sequela in noma survivors due to destruction of
    orofacial structures. Reported in 54.4% of patients in an Ethiopian cohort
    and consistently described in the literature.
  phenotype_term:
    preferred_term: Speech impairment
    term:
      id: HP:0002167
      label: Abnormal speech pattern
  evidence:
  - reference: PMID:41282445
    reference_title: "Patterns of Noma (Cancrum Oris) Survivors in Ethiopia: A Retrospective, Multicentric, Cross-sectional Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Common clinical issues included eating difficulties (77%), speech challenges
      (54.4%), and trismus (38.8%).
    explanation: >-
      Clinical data from 103 noma survivors shows speech challenges in 54.4% of
      patients.
  - reference: PMID:12655218
    reference_title: "A history of noma, the \"Face of Poverty\"."
    supports: SUPPORT
    snippet: >-
      Patients who survive noma generally suffer from its sequelae, including
      serious facial disfigurement, trismus, oral incontinence, and speech
      problems.
    explanation: >-
      Confirms speech problems as a recognized sequela of noma.
- name: Trismus
  category: Craniofacial
  description: >-
    Restricted mouth opening is a frequent sequela among noma survivors. It is
    reported in 38.8% of patients in an Ethiopian survivor cohort and is also
    described historically among the severe functional sequelae of the disease.
  phenotype_term:
    preferred_term: Trismus
    term:
      id: HP:0000211
      label: Trismus
  evidence:
  - reference: PMID:41282445
    reference_title: "Patterns of Noma (Cancrum Oris) Survivors in Ethiopia: A Retrospective, Multicentric, Cross-sectional Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Common clinical issues included eating difficulties (77%), speech
      challenges (54.4%), and trismus (38.8%).
    explanation: >-
      Clinical data from 103 noma survivors shows trismus in 38.8% of patients.
  - reference: PMID:12655218
    reference_title: "A history of noma, the \"Face of Poverty\"."
    supports: SUPPORT
    snippet: >-
      Patients who survive noma generally suffer from its sequelae, including
      serious facial disfigurement, trismus, oral incontinence, and speech
      problems.
    explanation: >-
      Historical review identifies trismus as a recognized sequela of noma
      survival.
- name: Dental abnormalities
  category: Craniofacial
  description: >-
    Noma destroys hard tissues of the oral cavity including teeth and bone,
    leading to loss of dentition and destruction of alveolar structures.
  phenotype_term:
    preferred_term: Destruction of dentition
    term:
      id: HP:0000164
      label: Abnormality of the dentition
  evidence:
  - reference: PMID:12002813
    reference_title: "Oro-facial gangrene (noma/cancrum oris): pathogenetic mechanisms."
    supports: SUPPORT
    snippet: >-
      Cancrum oris (Noma) is a devastating infectious disease which destroys the
      soft and hard tissues of the oral and para-oral structures.
    explanation: >-
      Confirms destruction of hard tissues (including teeth and bone) as a feature
      of noma.
- name: Malnutrition
  category: Constitutional
  description: >-
    Malnutrition is both a predisposing risk factor and a comorbid feature seen
    in virtually all noma patients. It acts synergistically with infections to
    promote the immunodeficient state required for noma development.
  phenotype_term:
    preferred_term: Malnutrition
    term:
      id: HP:0004395
      label: Malnutrition
  evidence:
  - reference: PMID:28093536
    reference_title: "Noma: Overview of a Neglected Disease and Human Rights Violation."
    supports: SUPPORT
    snippet: >-
      The etiology of noma is multifactorial with malnutrition as an ever present
      factor, often in combination with concomitant diseases, such as measles,
      malaria, and human immunodeficiency virus (HIV), and poor oral hygiene.
    explanation: >-
      Malnutrition is identified as an ever-present factor in noma etiology.
  - reference: PMID:12837347
    reference_title: "Noma: an \"infectious\" disease of unknown aetiology."
    supports: SUPPORT
    snippet: >-
      malnutrition, a compromised immune system, poor oral hygiene and a lesion of
      the gingival mucosal barrier, and an unidentified bacterial factor acting as
      a trigger for the disease.
    explanation: >-
      Lists malnutrition as a key element of the plausible aetiology of noma.
treatments:
- name: Antibiotic Therapy
  description: >-
    Early antibiotic treatment is used during active noma to prevent gangrene or
    reduce the extent of tissue destruction.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:28093536
    reference_title: "Noma: Overview of a Neglected Disease and Human Rights Violation."
    supports: SUPPORT
    snippet: >-
      Early treatment with antibiotics may prevent gangrene or reduce its extent.
    explanation: >-
      Review article supports antibiotics as early treatment to prevent or limit
      gangrene.
- name: Surgical Rehabilitation
  description: >-
    Survivors with late-stage sequelae often require complex reconstructive
    surgery and rehabilitation to address facial disfigurement and functional
    impairment.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
  evidence:
  - reference: PMID:28093536
    reference_title: "Noma: Overview of a Neglected Disease and Human Rights Violation."
    supports: SUPPORT
    snippet: >-
      Late treatment consists of surgical rehabilitation, which is often complex.
    explanation: >-
      Review article supports surgical rehabilitation as late treatment for noma
      sequelae.
  - reference: PMID:41282445
    reference_title: "Patterns of Noma (Cancrum Oris) Survivors in Ethiopia: A Retrospective, Multicentric, Cross-sectional Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Although surgical reconstruction is effective, high complication rates and
      the need for multiple surgical procedures underscore the importance of
      comprehensive long-term care, including rehabilitation and psychological
      support.
    explanation: >-
      Clinical survivor cohort describes reconstruction, repeated procedures, and
      rehabilitation needs after noma.
- name: Nutritional Support
  description: >-
    Nutritional support and correction of malnutrition are important supportive
    interventions because malnutrition is an ever-present factor in noma etiology
    and contributes to immune compromise.
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
  evidence:
  - reference: DOI:10.58541/001c.71441
    reference_title: "A necrotic orofacial lesion presenting in an immunocompromised patient in the UK: case review with features of noma"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Immediate treatment began following admission, including intravenous
      antibiotics, oral care and nutritional supplementation, before a definitive
      clinical diagnosis of noma was made after a biopsy, which ruled out
      malignancy.
    explanation: >-
      Clinical report describes nutritional supplementation as part of immediate
      treatment for a patient diagnosed with noma.
references:
- reference: DOI:10.1016/j.pmedr.2024.102764
  title: "Noma in the WHO's list of neglected tropical diseases: A review of its impact on undeveloped and developing tropical regions"
  found_in:
  - Noma-deep-research-falcon.md
  findings:
  - statement: "Noma in the WHO's list of neglected tropical diseases: A review of its impact on undeveloped and developing tropical regions"
    supporting_text: "Noma in the WHO's list of neglected tropical diseases: A review of its impact on undeveloped and developing tropical regions"
- reference: DOI:10.1101/2025.02.07.24315593
  title: 'A systematic review of the noma evidence landscape: current knowledge and gaps'
  found_in:
  - Noma-deep-research-falcon.md
  findings:
  - statement: Noma (cancrum oris) is a severe gangrenous disease of the mouth and oro-facial structures.
    supporting_text: Noma (cancrum oris) is a severe gangrenous disease of the mouth and oro-facial structures.
    evidence:
    - reference: DOI:10.1101/2025.02.07.24315593
      reference_title: 'A systematic review of the noma evidence landscape: current knowledge and gaps'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Noma (cancrum oris) is a severe gangrenous disease of the mouth and oro-facial structures.
      explanation: Deep research cited this publication as relevant literature for Noma.
- reference: DOI:10.1136/bmjgh-2025-019152
  title: 'Noma as a neglected tropical disease: an opportunity to reconsider neglect in global health'
  found_in:
  - Noma-deep-research-falcon.md
  findings:
  - statement: 'Noma as a neglected tropical disease: an opportunity to reconsider neglect in global health'
    supporting_text: 'Noma as a neglected tropical disease: an opportunity to reconsider neglect in global health'
- reference: DOI:10.1177/00494755231175529
  title: 'Psychosocial aspects of Noma (Cancrum Oris) in sub-Saharan Africa: A scoping review'
  found_in:
  - Noma-deep-research-falcon.md
  findings:
  - statement: Noma is a neglected tropical disease of an underserved population.
    supporting_text: Noma is a neglected tropical disease of an underserved population.
    evidence:
    - reference: DOI:10.1177/00494755231175529
      reference_title: 'Psychosocial aspects of Noma (Cancrum Oris) in sub-Saharan Africa: A scoping review'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Noma is a neglected tropical disease of an underserved population.
      explanation: Deep research cited this publication as relevant literature for Noma.
- reference: DOI:10.1371/journal.pntd.0012177
  title: Noma finally recognised as a neglected tropical disease
  found_in:
  - Noma-deep-research-falcon.md
  findings:
  - statement: In December 2023, after decades of tireless advocacy from stakeholders and partners, the World Health Organization (WHO) gave noma the long overdue recognition as a neglected tropical disease.
    supporting_text: In December 2023, after decades of tireless advocacy from stakeholders and partners, the World Health Organization (WHO) gave noma the long overdue recognition as a neglected tropical disease.
    evidence:
    - reference: DOI:10.1371/journal.pntd.0012177
      reference_title: Noma finally recognised as a neglected tropical disease
      supports: SUPPORT
      evidence_source: OTHER
      snippet: In December 2023, after decades of tireless advocacy from stakeholders and partners, the World Health Organization (WHO) gave noma the long overdue recognition as a neglected tropical disease.
      explanation: Deep research cited this publication as relevant literature for Noma.
- reference: DOI:10.1371/journal.pntd.0012696
  title: 'Rapid assessment of noma: Reporting on forgotten and neglected disease in Ethiopia'
  found_in:
  - Noma-deep-research-falcon.md
  findings:
  - statement: Noma is a rapidly progressing, invasive, and debilitating orofacial disease that primarily affects the most vulnerable and marginalised populations worldwide.
    supporting_text: Noma is a rapidly progressing, invasive, and debilitating orofacial disease that primarily affects the most vulnerable and marginalised populations worldwide.
    evidence:
    - reference: DOI:10.1371/journal.pntd.0012696
      reference_title: 'Rapid assessment of noma: Reporting on forgotten and neglected disease in Ethiopia'
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Noma is a rapidly progressing, invasive, and debilitating orofacial disease that primarily affects the most vulnerable and marginalised populations worldwide.
      explanation: Deep research cited this publication as relevant literature for Noma.
- reference: DOI:10.1371/journal.pntd.0012818
  title: Estimated incidence and clinical presentation of Noma in Northern Nigeria (1999-2024)
  found_in:
  - Noma-deep-research-falcon.md
  findings:
  - statement: Noma (Cancrum Oris), a recent addition to the WHO list of neglected tropical diseases, is a severe, rapidly progressing necrotizing disease of the oral cavity and facial complex with a case fatality rate of 90% if untreated.
    supporting_text: Noma (Cancrum Oris), a recent addition to the WHO list of neglected tropical diseases, is a severe, rapidly progressing necrotizing disease of the oral cavity and facial complex with a case fatality rate of 90% if untreated.
    evidence:
    - reference: DOI:10.1371/journal.pntd.0012818
      reference_title: Estimated incidence and clinical presentation of Noma in Northern Nigeria (1999-2024)
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Noma (Cancrum Oris), a recent addition to the WHO list of neglected tropical diseases, is a severe, rapidly progressing necrotizing disease of the oral cavity and facial complex with a case fatality rate of 90% if untreated.
      explanation: Deep research cited this publication as relevant literature for Noma.
- reference: DOI:10.1371/journal.pntd.0012940
  title: Defining the noma research agenda
  found_in:
  - Noma-deep-research-falcon.md
  findings:
  - statement: A 1-day symposium brought together over 100 individuals with lived experience of noma, expertise in neglected tropical diseases, and public health, including researchers, health advocates, and clinicians.
    supporting_text: A 1-day symposium brought together over 100 individuals with lived experience of noma, expertise in neglected tropical diseases, and public health, including researchers, health advocates, and clinicians.
    evidence:
    - reference: DOI:10.1371/journal.pntd.0012940
      reference_title: Defining the noma research agenda
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: A 1-day symposium brought together over 100 individuals with lived experience of noma, expertise in neglected tropical diseases, and public health, including researchers, health advocates, and clinicians.
      explanation: Deep research cited this publication as relevant literature for Noma.
- reference: DOI:10.33448/rsd-v14i1.48022
  title: Noma in a Pacient whitout Sistemic Involvement
  found_in:
  - Noma-deep-research-falcon.md
  findings:
  - statement: Noma, also known as Cancrum oris or gangrenous stomatitis, is an infectious disease of bacterial origin, often in association with other microorganisms, affecting orofacial tissues and manifesting through a sequence of precursors.
    supporting_text: Noma, also known as Cancrum oris or gangrenous stomatitis, is an infectious disease of bacterial origin, often in association with other microorganisms, affecting orofacial tissues and manifesting through a sequence of precursors.
    evidence:
    - reference: DOI:10.33448/rsd-v14i1.48022
      reference_title: Noma in a Pacient whitout Sistemic Involvement
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Noma, also known as Cancrum oris or gangrenous stomatitis, is an infectious disease of bacterial origin, often in association with other microorganisms, affecting orofacial tissues and manifesting through a sequence of precursors.
      explanation: Deep research cited this publication as relevant literature for Noma.
- reference: DOI:10.3389/froh.2023.1095858
  title: The key players of dysbiosis in Noma disease; A systematic review of etiological studies
  found_in:
  - Noma-deep-research-falcon.md
  findings:
  - statement: Noma is a rapidly progressing periodontal disease with up to 90% mortality in developing countries.
    supporting_text: Noma is a rapidly progressing periodontal disease with up to 90% mortality in developing countries.
    evidence:
    - reference: DOI:10.3389/froh.2023.1095858
      reference_title: The key players of dysbiosis in Noma disease; A systematic review of etiological studies
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Noma is a rapidly progressing periodontal disease with up to 90% mortality in developing countries.
      explanation: Deep research cited this publication as relevant literature for Noma.
- reference: DOI:10.4236/health.2023.154023
  title: 'Influencing Factors for Social Acceptance of Noma (Cancrum Oris) Patients in Niger: A Hospital-Based Cross-Sectional Study'
  found_in:
  - Noma-deep-research-falcon.md
  findings:
  - statement: 'Influencing Factors for Social Acceptance of Noma (Cancrum Oris) Patients in Niger: A Hospital-Based Cross-Sectional Study'
    supporting_text: 'Influencing Factors for Social Acceptance of Noma (Cancrum Oris) Patients in Niger: A Hospital-Based Cross-Sectional Study'
- reference: DOI:10.58541/001c.71441
  title: 'A necrotic orofacial lesion presenting in an immunocompromised patient in the UK: case review with features of noma'
  found_in:
  - Noma-deep-research-falcon.md
  findings:
  - statement: Noma is a gangrenous and destructive orofacial disease.
    supporting_text: Noma is a gangrenous and destructive orofacial disease.
    evidence:
    - reference: DOI:10.58541/001c.71441
      reference_title: 'A necrotic orofacial lesion presenting in an immunocompromised patient in the UK: case review with features of noma'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Noma is a gangrenous and destructive orofacial disease.
      explanation: Deep research cited this publication as relevant literature for Noma.
📚

References & Deep Research

References

12
DOI:10.1016/j.pmedr.2024.102764
Noma in the WHO's list of neglected tropical diseases: A review of its impact on undeveloped and developing tropical regions
1 finding
Noma in the WHO's list of neglected tropical diseases: A review of its impact on undeveloped and developing tropical regions
"Noma in the WHO's list of neglected tropical diseases: A review of its impact on undeveloped and developing tropical regions"
DOI:10.1101/2025.02.07.24315593
A systematic review of the noma evidence landscape: current knowledge and gaps
1 finding
Noma (cancrum oris) is a severe gangrenous disease of the mouth and oro-facial structures.
"Noma (cancrum oris) is a severe gangrenous disease of the mouth and oro-facial structures."
Show evidence (1 reference)
DOI:10.1101/2025.02.07.24315593 SUPPORT Other
"Noma (cancrum oris) is a severe gangrenous disease of the mouth and oro-facial structures."
Deep research cited this publication as relevant literature for Noma.
DOI:10.1136/bmjgh-2025-019152
Noma as a neglected tropical disease: an opportunity to reconsider neglect in global health
1 finding
Noma as a neglected tropical disease: an opportunity to reconsider neglect in global health
"Noma as a neglected tropical disease: an opportunity to reconsider neglect in global health"
DOI:10.1177/00494755231175529
Psychosocial aspects of Noma (Cancrum Oris) in sub-Saharan Africa: A scoping review
1 finding
Noma is a neglected tropical disease of an underserved population.
"Noma is a neglected tropical disease of an underserved population."
Show evidence (1 reference)
DOI:10.1177/00494755231175529 SUPPORT Human Clinical
"Noma is a neglected tropical disease of an underserved population."
Deep research cited this publication as relevant literature for Noma.
DOI:10.1371/journal.pntd.0012177
Noma finally recognised as a neglected tropical disease
1 finding
In December 2023, after decades of tireless advocacy from stakeholders and partners, the World Health Organization (WHO) gave noma the long overdue recognition as a neglected tropical disease.
"In December 2023, after decades of tireless advocacy from stakeholders and partners, the World Health Organization (WHO) gave noma the long overdue recognition as a neglected tropical disease."
Show evidence (1 reference)
DOI:10.1371/journal.pntd.0012177 SUPPORT Other
"In December 2023, after decades of tireless advocacy from stakeholders and partners, the World Health Organization (WHO) gave noma the long overdue recognition as a neglected tropical disease."
Deep research cited this publication as relevant literature for Noma.
DOI:10.1371/journal.pntd.0012696
Rapid assessment of noma: Reporting on forgotten and neglected disease in Ethiopia
1 finding
Noma is a rapidly progressing, invasive, and debilitating orofacial disease that primarily affects the most vulnerable and marginalised populations worldwide.
"Noma is a rapidly progressing, invasive, and debilitating orofacial disease that primarily affects the most vulnerable and marginalised populations worldwide."
Show evidence (1 reference)
DOI:10.1371/journal.pntd.0012696 SUPPORT Other
"Noma is a rapidly progressing, invasive, and debilitating orofacial disease that primarily affects the most vulnerable and marginalised populations worldwide."
Deep research cited this publication as relevant literature for Noma.
DOI:10.1371/journal.pntd.0012818
Estimated incidence and clinical presentation of Noma in Northern Nigeria (1999-2024)
1 finding
Noma (Cancrum Oris), a recent addition to the WHO list of neglected tropical diseases, is a severe, rapidly progressing necrotizing disease of the oral cavity and facial complex with a case fatality rate of 90% if untreated.
"Noma (Cancrum Oris), a recent addition to the WHO list of neglected tropical diseases, is a severe, rapidly progressing necrotizing disease of the oral cavity and facial complex with a case fatality rate of 90% if untreated."
Show evidence (1 reference)
DOI:10.1371/journal.pntd.0012818 SUPPORT Other
"Noma (Cancrum Oris), a recent addition to the WHO list of neglected tropical diseases, is a severe, rapidly progressing necrotizing disease of the oral cavity and facial complex with a case fatality rate of 90% if untreated."
Deep research cited this publication as relevant literature for Noma.
DOI:10.1371/journal.pntd.0012940
Defining the noma research agenda
1 finding
A 1-day symposium brought together over 100 individuals with lived experience of noma, expertise in neglected tropical diseases, and public health, including researchers, health advocates, and clinicians.
"A 1-day symposium brought together over 100 individuals with lived experience of noma, expertise in neglected tropical diseases, and public health, including researchers, health advocates, and clinicians."
Show evidence (1 reference)
DOI:10.1371/journal.pntd.0012940 SUPPORT Human Clinical
"A 1-day symposium brought together over 100 individuals with lived experience of noma, expertise in neglected tropical diseases, and public health, including researchers, health advocates, and clinicians."
Deep research cited this publication as relevant literature for Noma.
DOI:10.33448/rsd-v14i1.48022
Noma in a Pacient whitout Sistemic Involvement
1 finding
Noma, also known as Cancrum oris or gangrenous stomatitis, is an infectious disease of bacterial origin, often in association with other microorganisms, affecting orofacial tissues and manifesting through a sequence of precursors.
"Noma, also known as Cancrum oris or gangrenous stomatitis, is an infectious disease of bacterial origin, often in association with other microorganisms, affecting orofacial tissues and manifesting through a sequence of precursors."
Show evidence (1 reference)
DOI:10.33448/rsd-v14i1.48022 SUPPORT Other
"Noma, also known as Cancrum oris or gangrenous stomatitis, is an infectious disease of bacterial origin, often in association with other microorganisms, affecting orofacial tissues and manifesting through a sequence of precursors."
Deep research cited this publication as relevant literature for Noma.
DOI:10.3389/froh.2023.1095858
The key players of dysbiosis in Noma disease; A systematic review of etiological studies
1 finding
Noma is a rapidly progressing periodontal disease with up to 90% mortality in developing countries.
"Noma is a rapidly progressing periodontal disease with up to 90% mortality in developing countries."
Show evidence (1 reference)
DOI:10.3389/froh.2023.1095858 SUPPORT Other
"Noma is a rapidly progressing periodontal disease with up to 90% mortality in developing countries."
Deep research cited this publication as relevant literature for Noma.
DOI:10.4236/health.2023.154023
Influencing Factors for Social Acceptance of Noma (Cancrum Oris) Patients in Niger: A Hospital-Based Cross-Sectional Study
1 finding
Influencing Factors for Social Acceptance of Noma (Cancrum Oris) Patients in Niger: A Hospital-Based Cross-Sectional Study
"Influencing Factors for Social Acceptance of Noma (Cancrum Oris) Patients in Niger: A Hospital-Based Cross-Sectional Study"
DOI:10.58541/001c.71441
A necrotic orofacial lesion presenting in an immunocompromised patient in the UK: case review with features of noma
1 finding
Noma is a gangrenous and destructive orofacial disease.
"Noma is a gangrenous and destructive orofacial disease."
Show evidence (1 reference)
DOI:10.58541/001c.71441 SUPPORT Human Clinical
"Noma is a gangrenous and destructive orofacial disease."
Deep research cited this publication as relevant literature for Noma.

Deep Research

1
Falcon ▸
Disease Characteristics Research Template
Edison Scientific Literature 34 citations 2026-04-04T15:38:02.035786

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

  • Disease Name: Noma
  • MONDO ID: (if available)
  • Category: Infectious Disease

Research Objectives

Please provide a comprehensive research report on Noma covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

  • What is the disease? Provide a concise overview.
  • What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
  • What are the common synonyms and alternative names?
  • Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

  • Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
  • Risk Factors:

    Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

  • Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  • Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
  • Protective Factors:

    Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

  • Genetic protective factors (protective variants, modifier alleles)
  • Environmental protective factors (diet, lifestyle, exposures that reduce risk)
  • Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

    Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

  • Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

    Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

  • Pathogenic Variants:
  • Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  • Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  • Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  • Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  • Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
  • Functional consequences (loss of function, gain of function, dominant negative)
  • Modifier Genes: Genes that modify disease severity or expression
  • Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

    Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

  • Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

    Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

  • Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

    Search first: CDC databases, WHO, PubMed, NHANES

  • Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

    Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

  • Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

    Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

  • Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

    Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

  • Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

    Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

  • Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

    Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

  • Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

    Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

  • Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

    Search first: PubMed, Gene Ontology, Reactome

  • Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

    Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

  • Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Molecular Profiling (if available):
  • Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  • Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  • Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
  • Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  • Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
  • Advanced Technologies (if applicable):
  • Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  • Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
  • Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  • Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

  • Organ Level:
  • Primary organs directly affected
  • Secondary organ involvement (complications, secondary effects)
  • Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

    Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

  • Tissue and Cell Level:
  • Specific tissue types affected (epithelial, connective, muscle, nervous)
  • Specific cell populations targeted (with Cell Ontology terms)

    Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

  • Subcellular Level:
  • Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

    Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

  • Localization:
  • Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
  • Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

  • Onset:
  • Typical age of onset (congenital, pediatric, adult, geriatric)
  • Onset pattern (acute, subacute, chronic, insidious)

    Search first: OMIM, Orphanet, HPO, PubMed

  • Progression:
  • Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
  • Progression rate (rapid, slow, variable)
  • Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  • Disease duration (self-limited, chronic lifelong)

    Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

  • Patterns:
  • Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
  • Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

  • Epidemiology:
  • Prevalence (cases per 100,000 at given time)
  • Incidence (new cases per 100,000 per year)

    Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

  • For Genetic Etiology:
  • Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  • Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
  • Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
  • Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
  • Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
  • Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
  • Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
  • Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
  • Population Demographics:
  • Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  • Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  • Geographic distribution of specific variants
  • Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
  • Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

  • Clinical Tests:
  • Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
  • Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  • Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
  • Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
  • Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
  • Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
  • Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
  • Genetic Testing:

    Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

  • Overview of recommended genetic testing approach
  • Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
  • Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
  • Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
  • Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
  • Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
  • Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
  • FISH > Search first: ClinVar, cytogenetics databases, PubMed
  • Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
  • Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
  • Omics-Based Diagnostics (if applicable):
  • RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
  • Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
  • Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
  • Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
  • Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
  • Clinical Criteria:
  • Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
  • Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
  • Screening:
  • Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

  • Survival and Mortality:
  • Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
  • Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
  • Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
  • Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
  • Morbidity and Function:
  • Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
  • Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
  • Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
  • Disease Course:
  • Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
  • Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
  • Prediction:
  • Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
  • Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

  • Pharmacotherapy:
  • Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  • Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
  • Advanced Therapeutics:
  • Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  • Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
  • RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
  • Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  • Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
  • Surgical and Interventional:
  • Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
  • Supportive and Rehabilitative:
  • Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
  • Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
  • Experimental:
  • Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
  • Treatment Outcomes:
  • Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
  • Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
  • Treatment Strategy:
  • Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
  • Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
  • Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

  • Prevention Levels:
  • Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
  • Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
  • Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
  • Immunization: Vaccine strategies (if applicable)

    Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

  • Screening and Early Detection:
  • Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
  • Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
  • Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
  • Behavioral Interventions: Lifestyle modifications to reduce risk

    Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

  • Counseling: Genetic counseling (risk assessment, family planning guidance)

    Search first: NSGC resources, ACMG guidelines, GeneReviews

  • Public Health:
  • Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
  • Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
  • Prophylaxis: Preventive medications or procedures

    Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

  • Taxonomy: Species affected (with NCBI Taxon identifiers)

    Search first: NCBI Taxonomy

  • Breed: Specific breeds affected (with VBO identifiers if applicable)

    Search first: VBO (Vertebrate Breed Ontology)

  • Gene: Orthologous genes in other species (with NCBI Gene IDs)

    Search first: NCBI Gene

  • Natural Disease:
  • Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  • Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
  • Comparative Biology:
  • Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
  • Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
  • Transmission (if applicable):
  • Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
  • Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

  • Model Types:
  • Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
  • Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  • Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
  • Genetic Models:
  • Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
  • Model Characteristics:
  • Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
  • Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
  • Applications:
  • Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
  • Resources:
  • Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic and clinical claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes from abstracts where possible to support key statements
  • Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Noma (Cancrum oris) — Comprehensive Disease Characteristics Report (Infectious Disease)

Executive summary

Noma (cancrum oris) is a rapidly progressive, necrotizing, gangrenous disease of the mouth and face that overwhelmingly affects young children living in extreme poverty and malnutrition, and is characterized by very high untreated mortality and severe lifelong facial and functional sequelae in survivors. Recent global-health developments include WHO’s official recognition of noma as a neglected tropical disease (NTD) in December 2023, which is expected to improve visibility, funding opportunities, surveillance, and research prioritization. (ainsworth2024nomafinallyrecognised pages 1-2, verma2024nomainthe pages 1-2)

1. Disease information

1.1 Overview / definition

Noma is described as a severe, rapidly progressive orofacial gangrene affecting the mouth and facial structures, typically in malnourished, immunocompromised children in resource-poor settings, and is widely considered polymicrobial and multifactorial rather than caused by a single pathogen. (verma2024nomainthe pages 1-2, uzochukwu2023thekeyplayers pages 1-2)

1.2 Key identifiers (available in retrieved sources)

  • ICD-10 (WHO): Evidence in retrieved literature indicates noma is listed under A69.0 as “necrotising ulcerative stomatitis,” with synonymous labels including Cancrum oris, Noma, and stomatitis gangraenosa. (dhanjal2021anecroticorofacial pages 2-3, juhasz2006dasverschwindenvon pages 11-16)
  • ICD-11: Not found in the retrieved full-text evidence in this run.
  • MeSH / Orphanet / MONDO: Not found in the retrieved full-text evidence in this run; therefore no MeSH descriptor ID, ORPHA code, or MONDO ID can be provided with tool-verifiable citations here.

1.3 Synonyms and alternative names

Synonyms used across recent and historical clinical literature include: cancrum oris, necrotising ulcerative stomatitis, gangrenous stomatitis, and related necrotizing periodontal disease terms reflecting the clinical continuum (necrotising ulcerative gingivitis/periodontitis/stomatitis). (maguire2025asystematicreview pages 1-4, dhanjal2021anecroticorofacial pages 2-3)

1.4 Evidence provenance (individual vs aggregated)

  • Many clinical descriptions come from case reports/series and retrospective hospital/mission records, reflecting limited population-based surveillance. (maguire2025asystematicreview pages 1-4, enbiale2024rapidassessmentof pages 1-2)
  • Aggregated synthesis is available via systematic and scoping reviews; however, evidence quality is frequently low and heterogeneous. (maguire2025asystematicreview pages 1-4, maguire2025asystematicreview pages 6-9)

2. Etiology

2.1 Disease causal factors (infectious, environmental, mechanistic)

Current understanding supports noma as an opportunistic condition emerging from oral microbiome dysbiosis in a host rendered vulnerable by malnutrition, immunosuppression, and poverty-related exposures (poor hygiene, unsafe water/sanitation, limited healthcare access). (agost2025nomainmozambique.b pages 36-39, verma2024nomainthe pages 1-2)

2.2 Risk factors (with quantitative data where available)

Across a systematic review of the noma evidence landscape (366 publications), the most frequently reported risk factors were: - Nutritional deficit reported in 38.8% of studies (142/366). (maguire2025asystematicreview pages 4-6) - Infectious comorbidities reported in 56.5% of risk-factor publications (152/269); measles was the leading infectious risk among these (35.5%, 54/152). (maguire2025asystematicreview pages 4-6) - Poor oral hygiene reported in 28% (75/269) of risk-factor publications. (maguire2025asystematicreview pages 4-6)

Additional commonly cited risk factors in recent reviews include poverty, immunocompromise (including HIV), inadequate sanitation/unsafe water, gingival lesions, diarrhoea and fever, low birth weight, and high parity. (verma2024nomainthe pages 1-2)

2.3 Protective factors

Protective factors are less consistently studied, but case-control and synthesis sources report potential protective associations including colostrum and caregiving/maternal factors, alongside plausible upstream preventive levers (breastfeeding support, vaccination, improved nutrition, and oral hygiene). (agost2025nomainmozambique.b pages 39-42, verma2024nomainthe pages 2-3)

2.4 Gene–environment interactions

No specific gene–environment interactions are established in the retrieved evidence. Some literature suggests multifactorial origins could include host predisposition interacting with environmental and microbial factors, but without identified loci or effect estimates. (braimah2025estimatedincidenceand pages 2-4)

3. Phenotypes

3.1 Core clinical phenotypes (with staging)

WHO-aligned staging (including a warning stage) is commonly described as: - Stage 0 (warning): simple gingivitis (gum bleeding/inflammation). (agost2025nomainmozambique. pages 28-31) - Stage 1: acute necrotising gingivitis (spontaneous gum bleeding, painful papillary ulceration, fetid breath, salivation). (agost2025nomainmozambique.b pages 28-31) - Stage 2: oedema (facial swelling, fever, painful cheek, mucosal extension, difficulty eating, lymphadenopathy). (agost2025nomainmozambique.b pages 28-31) - Stage 3: gangrene (well-demarcated necrosis that sloughs off, leaving facial/oral defects). (agost2025nomainmozambique.b pages 28-31) - Stage 4: scarring. - Stage 5: sequelae (functional and structural deficits). (verma2024nomainthe pages 1-2)

Typical signs and symptoms include severe pain, fever, oral ulceration, mucosal oedema, purulent discharge, extreme halitosis, with progression to facial tissue loss, trismus, and feeding/swallowing and speech difficulties in later stages. (dhanjal2021anecroticorofacial pages 2-3, verma2024nomainthe pages 1-2)

3.2 Phenotype frequencies (examples from retrieved evidence)

  • In a sequelae/survivor context, one source reports trismus (13.6%) among sequelae cases. (verma2024nomainthe pages 3-4)
  • A Mozambique survey/case series excerpt reports high frequencies among a small assessed group (N=23) such as halitosis (100% among those assessed), oedema (90%), fever (80%), pain (64%), necrosis (67%), and eating problems (86%), illustrating the symptomatic burden in documented cases. (agost2025nomainmozambique.a pages 76-80)

3.3 Quality-of-life impact

Survivors frequently experience lifelong facial disfigurement and functional impairment with substantial stigma and psychosocial harm. (verma2024nomainthe pages 1-2, onu2023psychosocialaspectsof pages 1-2)

3.4 Suggested HPO terms (examples; not exhaustive)

Based on the clinical features in retrieved evidence: - HP:0000153 (Oral ulcer) (supported by clinical descriptions of oral ulceration) (dhanjal2021anecroticorofacial pages 2-3) - HP:0012531 (Halitosis) (fetid breath/extreme halitosis) (agost2025nomainmozambique.b pages 28-31, dhanjal2021anecroticorofacial pages 2-3) - HP:0000470 (Facial edema) (agost2025nomainmozambique.b pages 28-31, verma2024nomainthe pages 1-2) - HP:0000213 (Trismus) (dhanjal2021anecroticorofacial pages 2-3, verma2024nomainthe pages 1-2) - HP:0002014 (Dysphagia) / feeding difficulty (difficulty eating/deglutition) (agost2025nomainmozambique.b pages 28-31, verma2024nomainthe pages 1-2) - HP:0001945 (Fever) (agost2025nomainmozambique.b pages 28-31, dhanjal2021anecroticorofacial pages 2-3)

4. Genetic/molecular information

4.1 Causal genes / pathogenic variants

Noma is not established as a monogenic disorder in the retrieved evidence; no causal genes or pathogenic variants are reported. (agost2025nomainmozambique. pages 36-39, maguire2025asystematicreview pages 4-6)

4.2 Modifier genes, epigenetics, chromosomal abnormalities

No modifier genes, epigenetic mechanisms, or chromosomal abnormalities are identified in the retrieved evidence.

5. Environmental information

Noma is strongly associated with poverty-related environments: inadequate sanitation/unsafe water, limited access to healthcare, and poor oral hygiene; these factors co-occur with malnutrition and infectious comorbidities. (verma2024nomainthe pages 1-2, maguire2025asystematicreview pages 4-6)

6. Mechanism / pathophysiology

6.1 Current mechanistic model (causal chain)

A convergent model described in recent etiologic reviews is: 1) Systemic vulnerability (severe malnutrition, immunosuppression, intercurrent infections) + local oral factors (poor hygiene, gingival injury) 2) → acute necrotising gingivitis as immediate precursor 3) → polymicrobial dysbiosis and invasive infection 4) → rapid tissue destruction involving inflammatory vascular injury, microthrombi and ischemic necrosis, producing centrifugal facial tissue loss. (agost2025nomainmozambique.b pages 36-39, agost2025nomainmozambique. pages 36-39)

6.2 Microbiological findings (etiology research)

A 2023 systematic review of etiological studies highlights dysbiosis and identifies spirochaetes and Prevotella intermedia as putative trigger organisms and Fusobacterium nucleatum as promoting biofilm formation in later stages, while emphasizing major methodological limitations and the need for longitudinal high-throughput studies. (uzochukwu2023thekeyplayers pages 1-2)

A broader evidence-landscape systematic review reports extreme heterogeneity: 117 microorganisms were observed across reported noma cases in reviewed publications, consistent with polymicrobial involvement. (maguire2025asystematicreview pages 1-4)

6.3 Proposed GO (biological process) and CL (cell type) terms (suggestions)

Given the described mechanisms (inflammation, necrosis, ischemia, polymicrobial infection): - GO suggestions: inflammatory response, response to bacterium, biofilm formation, blood vessel occlusion, ischemia, tissue necrosis (supported conceptually by vascular injury/ischemic necrosis and bacterial drivers). (agost2025nomainmozambique. pages 36-39) - CL suggestions: neutrophil, macrophage, vascular endothelial cell, oral keratinocyte/epithelial cell (conceptual mapping to described infection/inflammation and vascular injury). (agost2025nomainmozambique. pages 36-39)

6.4 Key knowledge gaps

Major gaps include lack of standardized case definitions in practice, sparse population-based surveillance, limited early-stage sampling, and insufficient molecular-level mechanistic evidence (e.g., defined cytokine pathways), motivating calls for longitudinal multi-omics (transcriptomics/metabolomics) and improved microbiology study design. (galli2025definingthenoma pages 2-5, agost2025nomainmozambique.b pages 36-39)

7. Anatomical structures affected

  • Primary: oral cavity and facial tissues (gingiva/oral mucosa, cheeks, lips, nose, jaw/underlying bone). (verma2024nomainthe pages 3-4, verma2024nomainthe pages 1-2)
  • Complications/sequelae: scarring, fistulas, TMJ ankylosis, severe trismus; major functional impacts on feeding and speech. (maguire2025asystematicreview pages 6-9, verma2024nomainthe pages 1-2)

UBERON suggestions (examples): oral mucosa, gingiva, cheek, lip, nose, maxilla/mandible.

8. Temporal development

Noma can progress extremely rapidly from early necrotizing gingival lesions to facial tissue destruction within a short timeframe (reported as within ~two weeks/“a fortnight” in one description). (agost2025nomainmozambique.b pages 28-31)

Disease course is often conceptualized by stages (0–5) from gingivitis to sequelae, with early stages potentially reversible with prompt care, and late stages dominated by scarring and structural defects. (agost2025nomainmozambique.b pages 28-31, verma2024nomainthe pages 1-2)

9. Inheritance and population

9.1 Epidemiology (recent synthesis)

Epidemiologic estimates remain highly uncertain and vary widely: - Recent summaries cite ~30,000–40,000 cases annually worldwide. (verma2024nomainthe pages 1-2) - Older WHO-derived estimates cited in recent literature include ~140,000 new cases/year and ~770,000 people living with sequelae. (verma2024nomainthe pages 2-3, enbiale2024rapidassessmentof pages 2-4) - Geographic distribution includes reports from 88 countries (1950–2019) with concentration in the Sahel “noma belt” (e.g., Nigeria, Niger, Chad). (verma2024nomainthe pages 2-3)

Examples of reported subnational incidence variability include Nigerian states ranging 0.6–3300 per 100,000, and eastern Ethiopia 1.64–13.4 per 100,000 (children 0–9), illustrating instability of estimates. (verma2024nomainthe pages 2-3)

9.2 Demographics

Noma primarily affects children aged ~2–6 years; some sources describe that most cases occur before age 10. (uzochukwu2023thekeyplayers pages 1-2, dhanjal2021anecroticorofacial pages 2-3)

10. Diagnostics

10.1 Clinical diagnosis

Diagnosis is primarily clinical. WHO case definitions quoted in retrieved evidence include: - Suspected case: “Any child with a mouth ulcer and other warning signs such as malnutrition, poor hygiene, recent illness from measles, persistent diarrhoea, or malaria”. (agost2025nomainmozambique. pages 39-42) - Confirmed case: “any person with a gangrenous disease which starts as gingival ulceration and spreads rapidly through the tissues of the mouth and face, destroying the soft and hard tissues”. (agost2025nomainmozambique. pages 39-42)

10.2 Differential diagnosis

Differentials include animal bites, burns, cleft lip, cutaneous leishmaniasis, necrotising fasciitis, facial cancers, syphilis, yaws, mucormycosis, noma neonatorum, and herpetic gingivostomatitis. (agost2025nomainmozambique. pages 39-42, dhanjal2021anecroticorofacial pages 2-3)

10.3 Supportive tests

Biopsy and microbiology cultures may be used in atypical cases to exclude malignancy and alternative infections; one case report documents biopsy ruling out malignancy with negative cultures, supporting diagnosis by exclusion plus clinical picture. (dhanjal2021anecroticorofacial pages 2-3)

11. Outcome / prognosis

11.1 Mortality and survival

Untreated mortality is commonly cited as ~80–90%, while treated cohorts can have substantially lower mortality; one treated-case series reports 8.5% mortality in Zinder, Niger. (enbiale2024rapidassessmentof pages 1-2, verma2024nomainthe pages 1-2)

11.2 Morbidity and disability

Survivors frequently experience severe facial disfigurement, scarring, fistulas, trismus, and functional impairment, contributing to social stigma and disability. (maguire2025asystematicreview pages 6-9, verma2024nomainthe pages 1-2)

12. Treatment

12.1 Acute management (typical components)

Acute treatment is commonly described as multidisciplinary, combining: - Antibiotics (examples include amoxicillin + metronidazole; ampicillin + gentamicin + metronidazole; amoxicillin/clavulanate + gentamicin + metronidazole; and other regimens reported historically). (verma2024nomainthe pages 4-7, agost2025nomainmozambique. pages 73-76) - Local oral/wound care including debridement and antiseptic mouth care (e.g., chlorhexidine) and wound dressings (e.g., sodium hypochlorite in a documented case pathway). (agost2025nomainmozambique. pages 73-76, maguire2025asystematicreview pages 14-16) - Nutrition and supportive care (rehydration, electrolyte management, high-calorie/high-protein diets, vitamin supplementation such as vitamin A cited in reviews). (verma2024nomainthe pages 4-7, verma2024nomainthe pages 1-2)

12.2 Surgical and rehabilitative care

For stages with sequelae, reconstructive surgery (flaps/grafts) is frequently required; systematic evidence indicates many reconstruction approaches are reported but comparative outcomes are sparse and heterogeneous. (maguire2025asystematicreview pages 6-9, maguire2025asystematicreview pages 14-16)

12.3 Evidence quality

A systematic review found very heterogeneous treatment reporting (381 different intervention descriptions across 352 publications) and no evidence of superiority of any antibiotic family, with only six interventional studies (101 patients) identified—highlighting the need for higher-quality trials and standardized care pathways. (maguire2025asystematicreview pages 6-9)

12.4 Suggested MAXO terms (examples)

  • Antibiotic therapy; wound debridement; antiseptic oral rinse; nutritional supplementation; reconstructive surgery; rehabilitation/physiotherapy for trismus.

13. Prevention

Prevention is largely risk-factor–targeted and integrated public health: - Improve nutrition and address severe malnutrition; support breastfeeding/colostrum where relevant. (agost2025nomainmozambique.b pages 39-42, verma2024nomainthe pages 1-2) - Strengthen childhood vaccination and management of infections such as measles (prominent infectious comorbidity). (maguire2025asystematicreview pages 4-6, verma2024nomainthe pages 1-2) - Improve oral hygiene and early management of necrotizing gingival lesions. (maguire2025asystematicreview pages 4-6, maguire2025asystematicreview pages 14-16) - Improve water/sanitation and access to basic healthcare and early detection/referral systems. (verma2024nomainthe pages 1-2, galli2025definingthenoma pages 6-8)

14. Other species / natural disease

No established zoonotic or routine cross-species transmission is described in retrieved evidence. Historical reports describe rare noma-like lesions in nonhuman animals (e.g., a dog report) but these are not established natural reservoirs. (agost2025nomainmozambique. pages 36-39)

15. Model organisms

No established animal model exists; historical, nonstandard induction of noma-like lesions has been described in cortisone-treated rats with dental manipulation, but this has not become a validated model. (agost2025nomainmozambique. pages 36-39)

Recent developments and latest research (prioritizing 2023–2024)

WHO recognition as NTD (policy milestone)

  • WHO officially recognized noma as an NTD in December 2023. (ainsworth2024nomafinallyrecognised pages 1-2)
  • A 2024 editorial emphasizes that recognition followed “decades of tireless advocacy” and should improve credibility and opportunities for resourcing, while cautioning that listing alone does not guarantee funds. (ainsworth2024nomafinallyrecognised pages 1-2, ainsworth2024nomafinallyrecognised pages 2-3)

2024 health-system assessment (Ethiopia)

A 2024 rapid assessment in Ethiopia extracted 69 noma case records (2015–2020), with 97% coming from two NGOs supporting surgical missions, and highlighted major policy and primary-care oral-health gaps (“lacks a national policy on noma” and “no formal oral health program within the primary healthcare”). (enbiale2024rapidassessmentof pages 1-2)

Psychosocial evidence (2023)

  • A 2023 scoping review reports: “one in three persons with Noma has a mental health condition” and documents stigma, social isolation, and economic harms, with estimated productivity loss costs of US$13.4–15 million in one cited analysis. (onu2023psychosocialaspectsof pages 1-2)
  • A 2023 Niger cross-sectional study (n=50) quantified social rejection patterns, including 86.7% rejection associated with cheek lesion site and 60% rejection among single adults. (issa2023influencingfactorsfor pages 1-3)

Current applications and real-world implementations

Noma care is often delivered through combinations of local facilities, specialist referral centers, and NGO-supported surgical missions/campaigns. Examples in retrieved evidence include referral to maxillofacial surgical wards and the use of routine antibiotics plus daily wound dressing at district facilities, with later specialist modification of antibiotics and ongoing wound care at local centers. (agost2025nomainmozambique. pages 73-76, agost2025nomainmozambique.a pages 73-76)

Expert opinions and analysis (authoritative sources)

  • WHO recognition is widely framed as a catalyst for integrating noma into NTD systems, improving surveillance and standardized case definitions, and building a research agenda emphasizing early detection and psychosocial impact. (galli2025definingthenoma pages 2-5, galli2025definingthenoma pages 6-8)
  • Recent reviews highlight that knowledge gaps—especially inconsistent case definition usage, sparse epidemiologic data, and weak interventional evidence—remain key bottlenecks despite growing global attention. (maguire2025asystematicreview pages 1-4, maguire2025asystematicreview pages 6-9)

Structured summary table

The following table compiles the most actionable, knowledge-base-ready facts (identifiers, epidemiology, risks, staging, diagnostics, treatments, psychosocial outcomes) from the retrieved evidence.

Domain Key facts (with numbers) Key sources
Identifiers / synonyms Canonical names: Noma, cancrum oris, gangrenous stomatitis, necrotising ulcerative stomatitis/stomatitis. ICD-10 evidence in retrieved sources: A69.0, listed as “necrotising ulcerative stomatitis,” with synonyms including Noma and cancrum oris. Formal MeSH/Orphanet/MONDO IDs were not available in retrieved context. (juhasz2006dasverschwindenvon pages 11-16, dhanjal2021anecroticorofacial pages 2-3, verma2024nomainthe pages 1-2)
Disease definition Severe, rapidly progressive orofacial gangrene/necrotising disease of the mouth and face, usually affecting children living in extreme poverty with malnutrition and poor sanitation; polymicrobial/multifactorial rather than linked to a single pathogen. (verma2024nomainthe pages 1-2, maguire2025asystematicreview pages 1-4, uzochukwu2023thekeyplayers pages 1-2)
WHO / policy development WHO officially recognized noma as a neglected tropical disease in December 2023. Expected implications: more visibility, funding opportunities, surveillance, standardized case definitions, integrated NTD programming, and research momentum. (galli2025definingthenoma pages 2-5, ainsworth2024nomafinallyrecognised pages 1-2, association2025nomaasa pages 1-2)
Epidemiology / distribution Burden estimates vary widely: 30,000–40,000 cases/year in recent summaries; older WHO-derived estimates cite 140,000 new cases/year and 770,000 people living with sequelae. Reported in 88 countries (1950–2019); concentrated in the Sahel/“noma belt” including Nigeria, Niger, Chad. Nigeria state estimates ranged 0.6–3300/100,000; eastern Ethiopia 1.64–13.4/100,000; northwest Nigeria up to 640/100,000. (verma2024nomainthe pages 1-2, verma2024nomainthe pages 2-3, issa2023influencingfactorsfor pages 1-3)
Age / demographics Primarily affects children 2–6 years old; some sources say 1–6 years. One review notes ~90% of global cases develop before age 10. Adult cases occur but are uncommon and often linked to immunosuppression or severe systemic illness. (uzochukwu2023thekeyplayers pages 1-2, issa2023influencingfactorsfor pages 1-3, dhanjal2021anecroticorofacial pages 2-3)
Mortality / prognosis Untreated mortality commonly cited as 80–90%; historical fatality in pre-antibiotic era 63–94%. Some treated cohorts report lower mortality, e.g. 8.5% in Zinder, Niger; penicillin/sulphonamide-era reports reduced fatality to about 15%. Survivors often have lifelong disfigurement and functional impairment. (enbiale2024rapidassessmentof pages 1-2, verma2024nomainthe pages 1-2, agost2025nomainmozambique.b pages 28-31)
Major risk factors Major reported risks: malnutrition, infectious comorbidities, poor oral hygiene, immunosuppression, poverty, inadequate sanitation/unsafe water, low socioeconomic status, gingival lesions, diarrhoea, fever, low birth weight, high parity. In a 2025 review, nutritional deficit appeared in 38.8% of all included publications; infectious comorbidities in 56.5% of risk-factor papers; measles was the leading infectious risk in 35.5% of infectious-risk papers; poor oral hygiene in 28% of risk-factor papers. (verma2024nomainthe pages 1-2, maguire2025asystematicreview pages 4-6, uzochukwu2023thekeyplayers pages 1-2)
Protective factors Reported protective factors are less well studied; cited factors include colostrum, breastfeeding, caregiver being married, mother as primary caretaker (case-control data), plus programmatic prevention targets: childhood vaccination, improved oral hygiene, nutrition support, clean water/sanitation, and access to basic healthcare. (agost2025nomainmozambique.a pages 39-42, agost2025nomainmozambique.b pages 39-42, verma2024nomainthe pages 2-3)
Pathophysiology / etiology Current view favors polymicrobial dysbiosis + host vulnerability rather than one causative organism. Reviews highlight spirochaetes and Prevotella intermedia as putative early trigger organisms, with Fusobacterium nucleatum implicated in later biofilm formation. No single microbial cause has been confirmed. (uzochukwu2023thekeyplayers pages 1-2, agost2025nomainmozambique. pages 36-39)
WHO staging / clinical hallmarks WHO-aligned natural history: Stage 0 simple gingivitis; Stage 1 acute necrotising gingivitis (gum bleeding, painful papillae ulceration, fetid breath, excessive salivation); Stage 2 oedema (facial swelling, painful cheek, fever, difficulty eating, lymphadenopathy); Stage 3 gangrene (well-demarcated necrosis sloughing off, leaving a hole); Stage 4 scarring; Stage 5 sequelae. Hallmarks include pain, halitosis, oedema, necrosis/gangrene, tissue loss, trismus, dysphagia/feeding difficulty, speech impairment. (agost2025nomainmozambique.b pages 28-31, agost2025nomainmozambique. pages 28-31, verma2024nomainthe pages 1-2)
Anatomy affected Primarily oral and facial soft/hard tissues: gingiva, oral mucosa, cheeks, lips, nose, and jaw/bone. One source notes nose involvement in about 50% of defects and cheek involvement around 28–32%; sequelae can include trismus and temporomandibular ankylosis. (verma2024nomainthe pages 3-4, maguire2025asystematicreview pages 6-9)
Diagnostics / case definitions Diagnosis is mainly clinical. WHO suspected case in retrieved text: “Any child with a mouth ulcer and other warning signs such as malnutrition, poor hygiene, recent illness from measles, persistent diarrhoea, or malaria.” WHO confirmed case: “any person with a gangrenous disease which starts as gingival ulceration and spreads rapidly through the tissues of the mouth and face, destroying the soft and hard tissues.” (agost2025nomainmozambique. pages 39-42)
Differential diagnosis / workup Differentials include animal bites, burns, cleft lip, cutaneous leishmaniasis, necrotising fasciitis, facial cancers, syphilis, yaws, mucormycosis, noma neonatorum, and acute herpetic gingivostomatitis. Biopsy and microbiology may help exclude malignancy or alternative infection, but are not definitive for classic noma. Imaging/labs may be used for systemic evaluation in case reports. (agost2025nomainmozambique. pages 39-42, dhanjal2021anecroticorofacial pages 2-3, santos2025nomaina pages 2-4)
Treatment Acute care combines antibiotics + wound care + nutrition + hydration. Reported regimens include amoxicillin + metronidazole; ampicillin + gentamicin + metronidazole; amoxicillin/clavulanate + gentamicin + metronidazole; penicillin or clindamycin in older literature. Local care includes debridement, chlorhexidine mouthwash, hydrogen peroxide/oral cleaning, sodium hypochlorite dressings, and sometimes honey dressings. Surgical care includes debridement, tooth extraction when needed, and reconstructive surgery/flaps/grafts for sequelae. (agost2025nomainmozambique. pages 73-76, verma2024nomainthe pages 4-7, maguire2025asystematicreview pages 14-16)
Treatment evidence quality / implementation Evidence is weak and heterogeneous: 352/366 studies (96%) reported some treatment detail, but 381 different interventions were described; antibiotics were reported in 176 studies with no evidence that any antibiotic family is superior. Only 6 interventional studies (101 patients) were identified. Specialized care settings include the Noma Children’s Hospital, Sokoto and NGO-supported surgical missions/campaigns in Ethiopia and Mozambique. (maguire2025asystematicreview pages 6-9, maguire2025asystematicreview pages 4-6, braimah2025estimatedincidenceand pages 2-4, enbiale2024rapidassessmentof pages 1-2)
Psychosocial impact Severe stigma and social exclusion are common. A 2023 scoping review reported “one in three” people with noma has a mental health condition. In a Niger cross-sectional study (n=50), cheek lesions had 86.7% social rejection and single adults 60.0% rejection; acceptance was higher in younger children and those with earlier/acute care. Estimated indirect productivity losses were US$13.4–15 million in one cited analysis. (onu2023psychosocialaspectsof pages 1-2, issa2023influencingfactorsfor pages 1-3)

Table: This table compiles the main structured facts on noma (cancrum oris) from the retrieved evidence, including identifiers, burden estimates, risk factors, staging, diagnosis, treatment, and psychosocial burden. It is designed as a compact knowledge-base-ready reference with citation IDs for traceability.

Notes on evidence limitations (important for knowledge base curation)

  • This tool-assisted run could not retrieve formal MeSH descriptor IDs, Orphanet ORPHA, or MONDO identifiers with citable evidence; ICD-11 codes were also not captured in retrieved texts.
  • Epidemiology is highly uncertain and varies by method, case definitions, and under-ascertainment.
  • Molecular and cytokine pathway-level mechanisms remain poorly defined in the retrieved evidence and are repeatedly flagged as gaps requiring longitudinal, early-stage sampling and multi-omics studies. (agost2025nomainmozambique.b pages 36-39, galli2025definingthenoma pages 2-5)

References

  1. (ainsworth2024nomafinallyrecognised pages 1-2): Stuart Ainsworth. Noma finally recognised as a neglected tropical disease. PLOS Neglected Tropical Diseases, 18:e0012177, May 2024. URL: https://doi.org/10.1371/journal.pntd.0012177, doi:10.1371/journal.pntd.0012177. This article has 5 citations and is from a domain leading peer-reviewed journal.

  2. (verma2024nomainthe pages 1-2): Amogh Verma, Amna Zaheer, Areeba Ahsan, Ayush Anand, Hashem Abu Serhan, Mahalaqua Nazli Khatib, Quazi Syed Zahiruddin, Abhay M Gaidhane, Neelima Kukreti, Sarvesh Rustagi, Prakasini Satapathy, Divya Sharma, Mithhil Arora, and Rakesh Kumar Sharma. Noma in the who's list of neglected tropical diseases: a review of its impact on undeveloped and developing tropical regions. Preventive Medicine Reports, 43:102764, Jul 2024. URL: https://doi.org/10.1016/j.pmedr.2024.102764, doi:10.1016/j.pmedr.2024.102764. This article has 11 citations and is from a peer-reviewed journal.

  3. (uzochukwu2023thekeyplayers pages 1-2): Ifeanyi Uzochukwu, David Moyes, Gordon Proctor, and Mark Ide. The key players of dysbiosis in noma disease; a systematic review of etiological studies. Frontiers in Oral Health, Mar 2023. URL: https://doi.org/10.3389/froh.2023.1095858, doi:10.3389/froh.2023.1095858. This article has 15 citations and is from a peer-reviewed journal.

  4. (dhanjal2021anecroticorofacial pages 2-3): Gagandip Singh Dhanjal, Kelvin David Mizen, and Jerome Nigel Philip. A necrotic orofacial lesion presenting in an immunocompromised patient in the uk: case review with features of noma. Journal of the Irish Dental Association, Oct 2021. URL: https://doi.org/10.58541/001c.71441, doi:10.58541/001c.71441. This article has 0 citations.

  5. (juhasz2006dasverschwindenvon pages 11-16): J Juhász. Das verschwinden von noma in europa in der ersten hälfte des 20. jahrhunderts. Unknown journal, 2006.

  6. (maguire2025asystematicreview pages 1-4): Brittany J. Maguire, Rujan Shrestha, Prabin Dahal, Roland Ngu, Lionel Nizigama, Sumayyah Rashan, Poojan Shrestha, Elinor Harriss, Paul N. Newton, Yuka Makino, Benoit Varenne, and Philippe J. Guérin. A systematic review of the noma evidence landscape: current knowledge and gaps. MedRxiv, Feb 2025. URL: https://doi.org/10.1101/2025.02.07.24315593, doi:10.1101/2025.02.07.24315593. This article has 3 citations.

  7. (enbiale2024rapidassessmentof pages 1-2): Wendemagegn Enbiale. Rapid assessment of noma: reporting on forgotten and neglected disease in ethiopia. PLOS Neglected Tropical Diseases, 18:e0012696, Dec 2024. URL: https://doi.org/10.1371/journal.pntd.0012696, doi:10.1371/journal.pntd.0012696. This article has 0 citations and is from a domain leading peer-reviewed journal.

  8. (maguire2025asystematicreview pages 6-9): Brittany J. Maguire, Rujan Shrestha, Prabin Dahal, Roland Ngu, Lionel Nizigama, Sumayyah Rashan, Poojan Shrestha, Elinor Harriss, Paul N. Newton, Yuka Makino, Benoit Varenne, and Philippe J. Guérin. A systematic review of the noma evidence landscape: current knowledge and gaps. MedRxiv, Feb 2025. URL: https://doi.org/10.1101/2025.02.07.24315593, doi:10.1101/2025.02.07.24315593. This article has 3 citations.

  9. (agost2025nomainmozambique.b pages 36-39): M Ribes Agost. Noma in mozambique. epidemiological efforts to uncover a neglected disease. Unknown journal, 2025.

  10. (maguire2025asystematicreview pages 4-6): Brittany J. Maguire, Rujan Shrestha, Prabin Dahal, Roland Ngu, Lionel Nizigama, Sumayyah Rashan, Poojan Shrestha, Elinor Harriss, Paul N. Newton, Yuka Makino, Benoit Varenne, and Philippe J. Guérin. A systematic review of the noma evidence landscape: current knowledge and gaps. MedRxiv, Feb 2025. URL: https://doi.org/10.1101/2025.02.07.24315593, doi:10.1101/2025.02.07.24315593. This article has 3 citations.

  11. (agost2025nomainmozambique.b pages 39-42): M Ribes Agost. Noma in mozambique. epidemiological efforts to uncover a neglected disease. Unknown journal, 2025.

  12. (verma2024nomainthe pages 2-3): Amogh Verma, Amna Zaheer, Areeba Ahsan, Ayush Anand, Hashem Abu Serhan, Mahalaqua Nazli Khatib, Quazi Syed Zahiruddin, Abhay M Gaidhane, Neelima Kukreti, Sarvesh Rustagi, Prakasini Satapathy, Divya Sharma, Mithhil Arora, and Rakesh Kumar Sharma. Noma in the who's list of neglected tropical diseases: a review of its impact on undeveloped and developing tropical regions. Preventive Medicine Reports, 43:102764, Jul 2024. URL: https://doi.org/10.1016/j.pmedr.2024.102764, doi:10.1016/j.pmedr.2024.102764. This article has 11 citations and is from a peer-reviewed journal.

  13. (braimah2025estimatedincidenceand pages 2-4): Ramat Oyebunmi Braimah, John Adeoye, Abdurrazaq Olanrewaju Taiwo, Seidu Bello, Mujtaba Bala, Azeez Butali, Bruno Oludare Ile-Ogedengbe, and Abubakar Abdullahi Bello. Estimated incidence and clinical presentation of noma in northern nigeria (1999–2024). PLOS Neglected Tropical Diseases, 19:e0012818, May 2025. URL: https://doi.org/10.1371/journal.pntd.0012818, doi:10.1371/journal.pntd.0012818. This article has 5 citations and is from a domain leading peer-reviewed journal.

  14. (agost2025nomainmozambique. pages 28-31): M Ribes Agost. Noma in mozambique. epidemiological efforts to uncover a neglected disease. Unknown journal, 2025.

  15. (agost2025nomainmozambique.b pages 28-31): M Ribes Agost. Noma in mozambique. epidemiological efforts to uncover a neglected disease. Unknown journal, 2025.

  16. (verma2024nomainthe pages 3-4): Amogh Verma, Amna Zaheer, Areeba Ahsan, Ayush Anand, Hashem Abu Serhan, Mahalaqua Nazli Khatib, Quazi Syed Zahiruddin, Abhay M Gaidhane, Neelima Kukreti, Sarvesh Rustagi, Prakasini Satapathy, Divya Sharma, Mithhil Arora, and Rakesh Kumar Sharma. Noma in the who's list of neglected tropical diseases: a review of its impact on undeveloped and developing tropical regions. Preventive Medicine Reports, 43:102764, Jul 2024. URL: https://doi.org/10.1016/j.pmedr.2024.102764, doi:10.1016/j.pmedr.2024.102764. This article has 11 citations and is from a peer-reviewed journal.

  17. (agost2025nomainmozambique.a pages 76-80): M Ribes Agost. Noma in mozambique. epidemiological efforts to uncover a neglected disease. Unknown journal, 2025.

  18. (onu2023psychosocialaspectsof pages 1-2): Justus U. Onu, Deborah O. Aluh, and Charles N. Ononiwu. Psychosocial aspects of noma (cancrum oris) in sub-saharan africa: a scoping review. Tropical Doctor, 53:470-474, May 2023. URL: https://doi.org/10.1177/00494755231175529, doi:10.1177/00494755231175529. This article has 8 citations and is from a peer-reviewed journal.

  19. (agost2025nomainmozambique. pages 36-39): M Ribes Agost. Noma in mozambique. epidemiological efforts to uncover a neglected disease. Unknown journal, 2025.

  20. (galli2025definingthenoma pages 2-5): Anaïs Galli, Marianne Comparet, Daniel Argaw Dagne, Denise Baratti-Mayer, Thi H. Cao, Philippe J. Guérin, Maria Guevara, Manuel W. Hetzel, Claire Jeantet, Emmanuel Kabengele Mpinga, Valter Muendane, Mulikat Okanlawon, Erika Placella, Marta Ribes, Mark Sherlock, Jürg Utzinger, and Peter Steinmann. Defining the noma research agenda. PLOS Neglected Tropical Diseases, 19:e0012940, Apr 2025. URL: https://doi.org/10.1371/journal.pntd.0012940, doi:10.1371/journal.pntd.0012940. This article has 3 citations and is from a domain leading peer-reviewed journal.

  21. (enbiale2024rapidassessmentof pages 2-4): Wendemagegn Enbiale. Rapid assessment of noma: reporting on forgotten and neglected disease in ethiopia. PLOS Neglected Tropical Diseases, 18:e0012696, Dec 2024. URL: https://doi.org/10.1371/journal.pntd.0012696, doi:10.1371/journal.pntd.0012696. This article has 0 citations and is from a domain leading peer-reviewed journal.

  22. (agost2025nomainmozambique. pages 39-42): M Ribes Agost. Noma in mozambique. epidemiological efforts to uncover a neglected disease. Unknown journal, 2025.

  23. (verma2024nomainthe pages 4-7): Amogh Verma, Amna Zaheer, Areeba Ahsan, Ayush Anand, Hashem Abu Serhan, Mahalaqua Nazli Khatib, Quazi Syed Zahiruddin, Abhay M Gaidhane, Neelima Kukreti, Sarvesh Rustagi, Prakasini Satapathy, Divya Sharma, Mithhil Arora, and Rakesh Kumar Sharma. Noma in the who's list of neglected tropical diseases: a review of its impact on undeveloped and developing tropical regions. Preventive Medicine Reports, 43:102764, Jul 2024. URL: https://doi.org/10.1016/j.pmedr.2024.102764, doi:10.1016/j.pmedr.2024.102764. This article has 11 citations and is from a peer-reviewed journal.

  24. (agost2025nomainmozambique. pages 73-76): M Ribes Agost. Noma in mozambique. epidemiological efforts to uncover a neglected disease. Unknown journal, 2025.

  25. (maguire2025asystematicreview pages 14-16): Brittany J. Maguire, Rujan Shrestha, Prabin Dahal, Roland Ngu, Lionel Nizigama, Sumayyah Rashan, Poojan Shrestha, Elinor Harriss, Paul N. Newton, Yuka Makino, Benoit Varenne, and Philippe J. Guérin. A systematic review of the noma evidence landscape: current knowledge and gaps. MedRxiv, Feb 2025. URL: https://doi.org/10.1101/2025.02.07.24315593, doi:10.1101/2025.02.07.24315593. This article has 3 citations.

  26. (galli2025definingthenoma pages 6-8): Anaïs Galli, Marianne Comparet, Daniel Argaw Dagne, Denise Baratti-Mayer, Thi H. Cao, Philippe J. Guérin, Maria Guevara, Manuel W. Hetzel, Claire Jeantet, Emmanuel Kabengele Mpinga, Valter Muendane, Mulikat Okanlawon, Erika Placella, Marta Ribes, Mark Sherlock, Jürg Utzinger, and Peter Steinmann. Defining the noma research agenda. PLOS Neglected Tropical Diseases, 19:e0012940, Apr 2025. URL: https://doi.org/10.1371/journal.pntd.0012940, doi:10.1371/journal.pntd.0012940. This article has 3 citations and is from a domain leading peer-reviewed journal.

  27. (ainsworth2024nomafinallyrecognised pages 2-3): Stuart Ainsworth. Noma finally recognised as a neglected tropical disease. PLOS Neglected Tropical Diseases, 18:e0012177, May 2024. URL: https://doi.org/10.1371/journal.pntd.0012177, doi:10.1371/journal.pntd.0012177. This article has 5 citations and is from a domain leading peer-reviewed journal.

  28. (issa2023influencingfactorsfor pages 1-3): Abdou Hassane Issa, Kadre Alio Kadre Ousmane, Elhadj Ousmane Hamady Issa, Jiahao Shen, Maiga Djibo Douma, Alkassoum Salifou Ibrahim, Moeng Eva, and Ying Guan. Influencing factors for social acceptance of noma (cancrum oris) patients in niger: a hospital-based cross-sectional study. Health, 15:326-348, Jan 2023. URL: https://doi.org/10.4236/health.2023.154023, doi:10.4236/health.2023.154023. This article has 6 citations and is from a peer-reviewed journal.

  29. (agost2025nomainmozambique.a pages 73-76): M Ribes Agost. Noma in mozambique. epidemiological efforts to uncover a neglected disease. Unknown journal, 2025.

  30. (association2025nomaasa pages 1-2): Elysium Noma Survivors Association, Dan Izzett, Barbara Izzett, Alice Trotter, João Nunes, Ioana Cismas, Claire Jeantet, Emmanuel Kabengele, Habib Benzian, Heron Gebretsadik, Laura Merrill, Marta Ribes, Marianne Comparet, Mark Sherlock, and Himani Bhakuni. Noma as a neglected tropical disease: an opportunity to reconsider neglect in global health. BMJ Global Health, 10:e019152, Aug 2025. URL: https://doi.org/10.1136/bmjgh-2025-019152, doi:10.1136/bmjgh-2025-019152. This article has 0 citations and is from a peer-reviewed journal.

  31. (agost2025nomainmozambique.a pages 39-42): M Ribes Agost. Noma in mozambique. epidemiological efforts to uncover a neglected disease. Unknown journal, 2025.

  32. (santos2025nomaina pages 2-4): Vinícius Cezak Santos, Rafael Ferreira, Gleyson Kleber do Amaral Silva, Gustavo Silva Pelissaro, Elerson Gaetti-Jardim Júnior, and Ellen Cristina Gaetti-Jardim. Noma in a pacient whitout sistemic involvement. Research, Society and Development, 14:e4014148022, Jan 2025. URL: https://doi.org/10.33448/rsd-v14i1.48022, doi:10.33448/rsd-v14i1.48022. This article has 0 citations.